Researchers

ARIMA Shuji

ARIMA Shuji: Professor/Senior Staff

Faculty	Department of Medicine / Graduate School of Medical Sciences
Researchmap	https://researchmap.jp/read0208280

Education and Career

Academic & Professional Experience

Nov. 2011 - Today , Kindai University Faculty of Medicine 主任教授

Research Activities

Research Areas

Life sciences, Nephrology
Life sciences, Cardiology
Life sciences, Internal medicine - General

Research Interests

腎臓内科学

Published Papers

腹膜透析カテーテルの皮下での屈曲に対して，チタニウムエクステンダーを用いて屈曲部バイパス術を行った1例
今西茜衣里; 坂口美佳; 三木美帆; 福田雄基; 山根雅智; 岡田宜孝; 高橋実代; 清水和幸; 古林法大; 中野志仁; 中谷嘉寿; 有馬秀二
日本透析医学会雑誌 57 (10) , 449-454, Oct. 2024 , Refereed
Nesfatin-1 and tubulointerstitial damage in diabetic kidney disease: A possible biomarker for the histological severity
Sayoko Miyake; Yoshihisa Nakatani; Yukihito Nakano; Norihiro Kobayashi; Kazuyuki Shimizu; Shuji Arima
Acta Med Kindai Univ 47 (2) , 17-25, Dec. 2022 , Refereed
血性排液を伴う非外傷性腎破裂を来した腹膜透析患者の一例
樋口敦; 中野志仁; 樋口侑子; 高橋実代; 坂野恵里; 清水和幸; 三宅佐代子; 古林法大; 中谷嘉寿; 有馬秀二; 坂口美佳
大阪透析研究会会誌 39 (2) , 167-171, Sep. 2022

内科【高血圧診療Update-「高血圧治療ガイドライン2019」で何が変わるのか？】臓器障害を合併する高血圧腎疾患合併高血圧 , 有馬秀二 , 南江堂 , Feb. 2020
認定医・専門医のための輸液・電解質・酸塩基平衡 , 下澤達雄; 有馬秀二 , 中山書店 , 19, Jun. 2013
内分泌性高血圧 , 高見勝弘; 有馬秀二 , 南山堂 , May. 2013

高齢者糖尿病性腎症の血清Nesfatin-1濃度と腎組織障害及び腎予後についての検討 , 中谷嘉寿; 岡田宜孝; 古林法大; 中野志仁; 有馬秀二 , 第35回日本糖尿病性腎症研究会 , 30, Nov. 2024
福田雄基古林法大三木美帆清水和幸中野志仁坂口美佳中谷嘉寿有馬秀二 , 福田雄基; 古林法大; 三木美帆; 清水和幸; 中野志仁; 坂口美佳; 中谷嘉寿; 有馬秀二 , 第30回日本腹膜透析医学会学術集会・総会 , 16, Nov. 2024
The Effect of Nucleobindin-2 on Tubular Cells and Mitochondria and its Mechanism , Yoshihisa Nakatani; Yukihito Nakano; Shuji Arima , American Society of Nephrology Kidney Week 2024 , 26, Oct. 2024

Differential effects of angiotensin II receptor blocker and losartan/hydrochlorothiazide combination on central blood pressure and augmentation index , Hirohito Metoki; Hirohito Metoki; Taku Obara; Taku Obara; Taku Obara; Taku Obara; Kei Asayama; Kei Asayama; Kei Asayama; Michihiro Satoh; Michihiro Satoh; Miki Hosaka; Noha Elnagar; Yoshinori Miyawaki; Iwao Kojima; Takayoshi Ohkubo; Takayoshi Ohkubo; Takayoshi Ohkubo; Yutaka Imai; Yutaka Imai; Ryusuke Inoue; Junichiro Hashimoto; Masahiro Kikuya; Kazuhito Totsune; Motoya Nakagawa; Shigemichi Tanaka; Kotaro Nakamura; Nanako Hiwatari; Mutsuo Watanabe; Kenji Ito; Ruriko Mori; Hiroki Hoshi; Shuichi Sasaki; Daisuke Nakayama; Kouzou Ohta; Hiroshi Shishido; Youkou Emura; Hideo Odaka; Norihisa Kumasaka; Kazuteru Ohhira; Kuninobu Nihei; Kiyoto Ishibashi; Mitsutoshi Kato; Kiyoshi Uchiba; Masaaki Miyakawa; Hisao Mori; Takao Sugawara; Nobuhisa Yamada; Naoto Yagi; Yutaka Hatori; Tomoko Gomi; Toshio Ikeda; Takeshi Koitabashi; Shuji Arima; Masao Hiwatari , Clinical and Experimental Hypertension , 37 , 294 , 302 , 1, Jul. 2015
Summary:© 2015 Informa Healthcare USA, Inc. Central systolic blood pressure (CSBP) may be a better predictor of cardiovascular risk than clinic brachial (B)SBP. The effects of dose increment from medium dose of angiotensin II receptor blockers (ARBs) to the maximum dose of ARBs (maximum) and changing from medium dose of ARBs to losartan 50 mg/hydrochlorothiazide 12.5mg combination (combination) were compared in hypertensive patients in whom monotherapy with a medium ARB dose did not achieve goal home SBP (135 mmHg). Four weeks after treatment with a medium ARB dose monotherapy, those whose home SBP level was above 135mmHg were randomized to receive the maximum ARB dose (n=101) or the combination (n=99) once daily for 8 weeks. Both regimens significantly decreased BSBP and CSBP, while a decrease in BSBP and CSBP was greater with combination. The maximum significantly decreased augmentation index (AIx), while the combination did not. The rate of a decrease in reflection to decrease in CSBP was greater in the maximum than in the combination. In the elderly subgroup, the combination more effectively lowered BSBP than the maximum, and only the combination decreased CSBP. However, in the young subgroup, the maximum decreased AIx more than combination, while both regimens lowered CSBP and BSBP to a similar extent. It is explained in part that the maximum may affect pulse wave reflection more predominantly than the combination, especially in young subjects. A weak effect on pulse wave reflection and, thus, on CSBP, of the combination may be overcome by the potent antihypertensive effect of this regimen.
CKDの降圧治療薬としてT/L型Ca拮抗薬に求められること CKD診療ガイドライン2013からみた血圧管理 , 伊藤貞嘉; 長谷部直幸; 有馬秀二; 田村功一 , 血圧 , 21 , 2 , 151 , 159 , Feb. 2014
【あなたも名医!高血圧、再整理がっちり押さえたい最新の診療方法】 (第3章)高血圧の外来での薬物治療はどうする? 主な降圧薬の特徴と使用法 Ca拮抗薬 , 松岡稔明; 有馬秀二 , jmed mook , 20 , 56 , 61 , Jun. 2012